The Department of Health and Human Services has defended cuts to vaccine research with statements that mislead on the safety of mRNA technology, despite an extensive history of testing. “After a ...
A presentation by scientists on a work group for the Centers for Disease Control and Prevention’s vaccine advisory panel ...
MRNA is likely to have faced earnings pressure and pipeline setbacks as waning COVID-19 vaccine demand weighs on its outlook.
In a recent study published in the journal Nature Reviews Drug Discovery, researchers collate available literature on medical and industrial developments aimed at reducing the cellular toxicity of ...
Settlement reached over mRNA-based COVID vaccines CureVac and GSK get $740 million upfront, and royalties BioNTech's deal to buy CureVac on track GSK's own lawsuits against Pfizer, BioNTech unaffected ...
Hosted on MSN
HHS slashes funding for mRNA vaccine development
US Health and Human Services is “winding down” its mRNA vaccine development and will instead fund other vaccine platforms through the Biomedical Advanced Research and Development Authority, the agency ...
March 27 (Reuters) - The European Patent Office declared a patent owned by CureVac (5CV.DE), opens new tab, valid, after a challenge from drugmaker BioNTech (22UAy.DE), opens new tab, the company said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback